Literature DB >> 28655808

Chronic myeloid leukemia: room for improvement?

Michele Baccarani1, Fabrizio Pane2, Gianantonio Rosti3, Domenico Russo4, Giuseppe Saglio5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28655808      PMCID： PMC5566010          DOI： 10.3324/haematol.2017.166280

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Authors:  V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann
Journal:  Leukemia       Date:  2015-03-18       Impact factor: 11.528

2.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Authors:  Gabriel Etienne; Joëlle Guilhot; Delphine Rea; Françoise Rigal-Huguet; Franck Nicolini; Aude Charbonnier; Agnès Guerci-Bresler; Laurence Legros; Bruno Varet; Martine Gardembas; Viviane Dubruille; Michel Tulliez; Marie-Pierre Noel; Jean-Christophe Ianotto; Bruno Villemagne; Martin Carré; François Guilhot; Philippe Rousselot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Moving treatment-free remission into mainstream clinical practice in CML.

Authors:  Timothy P Hughes; David M Ross
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

4.  Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

Authors:  F Castagnetti; G Gugliotta; M Breccia; F Stagno; A Iurlo; F Albano; E Abruzzese; B Martino; L Levato; T Intermesoli; P Pregno; G Rossi; F Gherlinzoni; P Leoni; F Cavazzini; C Venturi; S Soverini; N Testoni; G Alimena; M Cavo; G Martinelli; F Pane; G Saglio; G Rosti; M Baccarani
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

5.  Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.

Authors:  Domenico Russo; Giovanni Martinelli; Michele Malagola; Cristina Skert; Simona Soverini; Ilaria Iacobucci; Antonio De Vivo; Nicoletta Testoni; Fausto Castagnetti; Gabriele Gugliotta; Diamante Turri; Micaela Bergamaschi; Michela Bergamaschi; Patrizia Pregno; Ester Pungolino; Fabio Stagno; Massimo Breccia; Bruno Martino; Tamara Intermesoli; Carmen Fava; Elisabetta Abruzzese; Mario Tiribelli; Catia Bigazzi; Bruno Mario Cesana; Gianantonio Rosti; Michele Baccarani
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

6.  Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Authors:  Martin Höglund; Fredrik Sandin; Karin Hellström; Mats Björeman; Magnus Björkholm; Mats Brune; Arta Dreimane; Marja Ekblom; Sören Lehmann; Per Ljungman; Claes Malm; Berit Markevärn; Kristina Myhr-Eriksson; Lotta Ohm; Ulla Olsson-Strömberg; Anders Själander; Hans Wadenvik; Bengt Simonsson; Leif Stenke; Johan Richter
Journal:  Blood       Date:  2013-07-10       Impact factor: 22.113

7.  Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.

Authors:  M Baccarani
Journal:  Leukemia       Date:  2017-02-03       Impact factor: 11.528

8.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

Authors:  Koji Sasaki; Sara S Strom; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Naveen Pemmaraju; Naval Daver; Preetesh Jain; Sherry Pierce; Hagop Kantarjian; Jorge E Cortes
Journal:  Lancet Haematol       Date:  2015-04-20       Impact factor: 18.959

9.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Authors:  A Hochhaus; G Saglio; T P Hughes; R A Larson; D-W Kim; S Issaragrisil; P D le Coutre; G Etienne; P E Dorlhiac-Llacer; R E Clark; I W Flinn; H Nakamae; B Donohue; W Deng; D Dalal; H D Menssen; H M Kantarjian
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

Review 10.  The concept of treatment-free remission in chronic myeloid leukemia.

Authors:  S Saußele; J Richter; A Hochhaus; F-X Mahon
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.